Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) recorded a 22% rise in attributable profit for the first quarter of 2026 to 2.28 billion yuan from 1.87 billion yuan a year prior, according to a Wednesday Hong Kong bourse filing.
Earnings per share jumped to 0.34 yuan from 0.30 yuan in the corresponding period of the previous fiscal year.
Operating revenue climbed 13% to 8.14 billion yuan from 7.21 billion yuan in the year-ago period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments